title: Rapamycin increases survival in ALS mice lacking mature lymphocytes.
abstract: BACKGROUND
  Amyotrophic Lateral Sclerosis (ALS) is a devastating progressive neurodegenerative disease. Disease pathophysiology is complex and not yet fully understood, but is proposed to include the accumulation of misfolded proteins, as aggregates are present in spinal cords from ALS patients and in ALS model organisms. Increasing autophagy is hypothesized to be protective in ALS as it removes these aggregates. Rapamycin is frequently used to increase autophagy, but is also a potent immune suppressor. To properly assess the role of rapamycin-induced autophagy, the immune suppressive role of rapamycin should be negated.
  
  
  RESULTS
  Autophagy is increased in the spinal cord of ALS mice. Dietary supplementation of rapamycin increases autophagy, but does not increase the survival of mutant SOD1 mice. To measure the effect of rapamycin in ALS independent of immunosuppression, we tested the effect of rapamycin in ALS mice deficient of mature lymphocytes. Our results show that rapamycin moderately increases the survival of these ALS mice deficient of mature lymphocytes.
  
  
  CONCLUSIONS
  Rapamycin could suppress protective immune responses while enhancing protective autophagy reactions during the ALS disease process. While these opposing effects can cancel each other out, the use of immunodeficient mice allows segregation of effects. Our results indicate that maximal therapeutic benefit may be achieved through the use of compounds that enhance autophagy without causing immune suppression.
authors.affiliation: Laboratory of Neurobiology, Vesalius Research Center, VIB, Leuven, Belgium. Ludo.VandenBosch@vib-kuleuven.be.
authors.forename: Kim A
authors.initials: KA
authors.lastname: Staats
authors.forename: Sara
authors.initials: S
authors.lastname: Hernandez
authors.forename: Susann
authors.initials: S
authors.lastname: Schönefeldt
authors.forename: André
authors.initials: A
authors.lastname: Bento-Abreu
authors.forename: James
authors.initials: J
authors.lastname: Dooley
authors.forename: Philip
authors.initials: P
authors.lastname: Van Damme
authors.forename: Adrian
authors.initials: A
authors.lastname: Liston
authors.forename: Wim
authors.initials: W
authors.lastname: Robberecht
authors.forename: Ludo
authors.initials: L
authors.lastname: Van Den Bosch
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000276:immunology / Q000473:pathology*; D000818:Animals; D001343:Autophagy / Q000187:drug effects*; D015153:Blotting, Western; D004195:Disease Models, Animal; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008214:Lymphocytes / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D020123:Sirolimus / Q000494:pharmacology*; D013116:Spinal Cord / Q000187:drug effects / Q000473:pathology
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus
references.citation: J Neuropathol Exp Neurol. 2011 May;70(5):349-59
references.pmid: 21487309
references.citation: Int J Mol Sci. 2011;12(10):6980-7003
references.pmid: 22072931
references.citation: Genes Dev. 2009 Oct 1;23(19):2294-306
references.pmid: 19762508
references.citation: Nature. 2009 Jul 16;460(7253):392-5
references.pmid: 19587680
references.citation: Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15024-9
references.pmid: 22932872
references.citation: CNS Neurol Disord Drug Targets. 2010 Jul;9(3):285-96
references.pmid: 20406182
references.citation: Brain. 2011 May;134(Pt 5):1293-314
references.pmid: 21596768
references.citation: Hum Mol Genet. 2013 Mar 15;22(6):1167-79
references.pmid: 23250913
references.citation: Cell. 1992 Mar 6;68(5):869-77
references.pmid: 1547488
references.citation: EMBO J. 1999 Mar 1;18(5):1303-8
references.pmid: 10064596
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15558-63
references.pmid: 18809917
references.citation: Nat Genet. 2004 Jun;36(6):585-95
references.pmid: 15146184
references.citation: J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):385-90
references.pmid: 19710046
references.citation: Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17913-8
references.pmid: 18997009
references.citation: Brain. 2010 Jan;133(Pt 1):93-104
references.pmid: 20007218
references.citation: Mol Aspects Med. 2011 Jun;32(3):159-221
references.pmid: 21840335
references.citation: Science. 1991 Aug 23;253(5022):905-9
references.pmid: 1715094
references.citation: J Biol Chem. 2011 Feb 4;286(5):3618-29
references.pmid: 21059646
references.citation: Clin Nutr. 2009 Dec;28(6):604-17
references.pmid: 19782443
references.citation: Neurobiol Aging. 2012 Aug;33(8):1829-32
references.pmid: 21763036
references.citation: Nat Rev Immunol. 2009 May;9(5):324-37
references.pmid: 19390566
references.citation: J Neurosci. 2009 Oct 28;29(43):13578-88
references.pmid: 19864570
references.citation: Brain Res. 2007 Sep 5;1167:112-7
references.pmid: 17689501
references.citation: Autophagy. 2011 Sep;7(9):985-92
references.pmid: 21628996
references.citation: Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1013-24
references.pmid: 16675207